Showing 4451-4460 of 5910 results for "".
- LumiThera Presents New Data from LIGHTSITE III Trial Showing Improvement in Vision in Intermediate Dry AMDhttps://modernod.com/news/lumithera-presents-new-data-from-lightsite-iii-trial-showing-improvement-in-vision-in-intermediate-dry-amd/2480930/LumiThera announced detailed findings in its LIGHTSITE III, multicenter clinical trial in non-neovascular age-related macular degeneration (AMD) subjects treated with photobiomodulation (PBM) using the Valeda Light Delivery System. LIGHTSITE III, a prospective, double-masked,
- BRIM Biotechnology Enters Trading in Taiwanhttps://modernod.com/news/brim-biotechnology-enters-otc-trading-in-taiwan/2480926/BRIM Biotechnology has entered OTC trading in Taiwan on June 23, 2022. Established in 2013, BRIM is a clinical-stage company developing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases. BRIM has several novel drug products
- Opus Genetics Appoints Ben Yerxa, PhD, as Permanent Chief Executive Officerhttps://modernod.com/news/opus-genetics-appoints-ben-yerxa-phd-as-permanent-chief-executive-officer/2480923/Opus Genetics announced the appointment of Ben Yerxa, PhD, as Chief Executive Officer. Dr. Yerxa previously served as acting CEO of Opus, in addition to former roles as CEO of the Foundation Fighting Blindness and the Retinal Degeneration (RD) Fund, the venture arm of th
- University of Wisconsin Eye Research Uncovers How Stem Cell Photoreceptors Reach Their Targetshttps://modernod.com/news/uw-eye-research-uncovers-how-stem-cell-photoreceptors-reach-their-targets/2480915/A new study reveals how photoreceptors grown from stem cells might extend biological wires, known as axons, to contact existing neurons. The finding has implications for future treatment of retinal diseases that cause blindness, including age-related macular degeneration (AMD) and rare disea
- Samsara Vision and Lansheng Medical “MyVision” Announce Collaboration to Commercialize the SING IMT in Chinahttps://modernod.com/news/samsara-vision-and-lansheng-medical-myvision-announce-collaboration-to-commercialize-the-sing-imt-in-china/2480907/Samsara Vision announced it will collaborate with Lansheng Medical “MyVision,” a China-based company focused on ophthalmology, to develop a clinical and commercial organization to support Samsara Vision’s SING IMT (Smaller-Incision New-Generation Implantable Miniature
- First-of-its-Kind Study Finds Artificial Intelligence Screenings Improve Eye Care Access in Sub-Saharan Africahttps://modernod.com/news/first-of-its-kind-study-finds-artificial-intelligence-screenings-improve-eye-care-access-in-sub-saharan-africa/2480906/Orbis announced new research findings demonstrating that diabetic retinopathy screenings supported by artificial intelligence (AI) enhanced patients’ speed and uptake of referral services in Rwanda, which can help reduce vision loss due to diabetes in the region. The study is
- Rayner Acquires Stake in Sustainable Surgical Instrument Belgian Manufacturer Hasa Optixhttps://modernod.com/news/rayner-acquires-stake-in-sustainable-surgical-instrument-belgian-manufacturer-hasa-optix/2480900/Rayner announced that it has entered into a commercial partnership and concurrently acquired a stake in Hasa Optix, a Brussels-based manufacturer of single use ophthalmic surgical instruments and instrument sets. The investment closed June 7, 2022. Financial terms of the deal
- Eyenovia Announces Planned Chief Executive Officer Transitionhttps://modernod.com/news/eyenovia-announces-planned-chief-executive-officer-transition/2480898/Eyenovia announced that Sean Ianchulev, MD, co-founder, chief medical officer, and chief executive officer, will step down as chief executive officer and transition to the role of non-executive Chairman of the Board. The definitive timeline for the transition will be determin
- NIH Study Confirms Benefit of Supplements for Slowing AMDhttps://modernod.com/news/nih-study-confirms-benefit-of-supplements-for-slowing-age-related-macular-degeneration-amd/2480894/The Age-Related Eye Disease Studies (AREDS and AREDS2) established that dietary supplements can slow progression of age-related macular degeneration (AMD), according to the Nationa
- Novartis Receives FDA Approval of Beovu for the Treatment of Diabetic Macular Edemahttps://modernod.com/news/novartis-announces-fda-approval-of-beovu-for-the-treatment-of-diabetic-macular-edema/2480891/Novartis announced that the FDA has approved Beovu (brolucizumab-dbll) 6 mg for the treatment of diabetic macular edema (DME). Today’s approval represents the second FDA-approved indication for Beovu, which was first approved for the treatment of wet age-related macular degeneration in